These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25512452)

  • 1. Reply to L. Cabel et al.
    Fehrenbacher L; Capra A; Habel L
    J Clin Oncol; 2015 Jan; 33(3):292-3. PubMed ID: 25512452
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to H.L. McArthur et al.
    Vaz-Luis I; Lin NU
    J Clin Oncol; 2015 Jan; 33(1):125. PubMed ID: 25403214
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognosis of t1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas.
    Cabel L; Péron J; Cottu PH; Rodrigues MJ
    J Clin Oncol; 2015 Jan; 33(3):291. PubMed ID: 25512462
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    McArthur HL; Morris PG; Hudis CA
    J Clin Oncol; 2015 Jan; 33(1):124-5. PubMed ID: 25403210
    [No Abstract]   [Full Text] [Related]  

  • 5. How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.
    Reeder-Hayes KE; Carey LA
    J Clin Oncol; 2014 Jul; 32(20):2122-4. PubMed ID: 24888811
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.
    Prat A; Baselga J
    J Clin Oncol; 2013 May; 31(14):1703-6. PubMed ID: 23569319
    [No Abstract]   [Full Text] [Related]  

  • 7. Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer.
    Lin NU
    J Clin Oncol; 2015 May; 33(14):1530-3. PubMed ID: 25847924
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
    Wolff AC; Hammond ME; Hayes DF
    J Natl Cancer Inst; 2012 Jun; 104(12):957-8. PubMed ID: 22581974
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to P.G. Gavin et al.
    Perez EA; Thompson EA; Ballman KV
    J Clin Oncol; 2015 Nov; 33(31):3672-3. PubMed ID: 26282664
    [No Abstract]   [Full Text] [Related]  

  • 10. [Modern pharmacological therapy of breast cancer].
    Láng I; Kahán Z; Hitre E; Dank M; Rubovszky G; Horváth Z; Kásler M
    Orv Hetil; 2012 Jan; 153(2):56-65. PubMed ID: 22217685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the value of the 21 gene recurrence score in HER2-negative patients?
    Rosman M; Mylander WC; Tafra L
    J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmaceutical therapy of breast cancer].
    Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
    Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
    [No Abstract]   [Full Text] [Related]  

  • 13. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
    Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
    J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 inhibitors in luminal breast cancer.
    Gnant M; Steger GG; Bartsch R
    Lancet Oncol; 2015 Jan; 16(1):2-3. PubMed ID: 25524801
    [No Abstract]   [Full Text] [Related]  

  • 15. Enlisting the Immune System to Cure Breast Cancer--A Recipe for Success.
    Adams S
    JAMA Oncol; 2016 Jan; 2(1):25-7. PubMed ID: 26468637
    [No Abstract]   [Full Text] [Related]  

  • 16. The taxane limbo: how low can we go?
    Hudis C; Dang C
    J Natl Cancer Inst; 2008 Jun; 100(11):761-3. PubMed ID: 18505966
    [No Abstract]   [Full Text] [Related]  

  • 17. [HER2-positive breast cancer: standard and double targeted therapy].
    Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
    Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant capecitabine for HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2017 Jul; 18(7):e375. PubMed ID: 28602775
    [No Abstract]   [Full Text] [Related]  

  • 19. Bevacizumab for advanced breast cancer: all tied up with a RIBBON?
    Burstein HJ
    J Clin Oncol; 2011 Apr; 29(10):1232-5. PubMed ID: 21383305
    [No Abstract]   [Full Text] [Related]  

  • 20. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
    Esteva FJ; Hortobagyi GN
    J Natl Cancer Inst; 2008 Apr; 100(8):521-3. PubMed ID: 18398093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.